Showing 1215 Results
2024 Annual Report
NPC published policy-relevant research and engaged with stakeholders throughout 2024 to foster evidence-based health policy discussions and inform decision-making. Learn more in the Annual Report…
ICER Analyses of “Unsupported” Drug Price Increases Misrepresent Spending Changes by Failing to Adjust for Inflation
A new study from the National Pharmaceutical Council finds that incorporating inflation adjustments would have substantially changed the findings ICER published in its most recent reports.
Inflation-Adjusted Analysis of ICER's Unsupported Price Increase Reports: Contextualizing Drug Spending Changes
Published in the Journal of Medical Economics, this study evaluated the economic context of “unsupported” drug price increases reported by the Institute for Clinical and Economic Research (ICER) and…
Improving Access to Gene Therapies: A Holistic View of Current Challenges and Future Policy Solutions in the United States
Published in the Journal of Comparative Effectiveness Research, this analysis provides a more holistic multistakeholder examination of the unique policy challenges associated with patient access to…
NPC Provides Comments to CMS on the Notice of Benefit and Payment Parameters (NBPP) for Calendar Year 2026
NPC submitted comments to the Centers for Medicare & Medicaid Services (CMS) regarding the proposed provisions to alter the affordability, quality, accessibility of Marketplace health insurance,…
Lessons from a Quantitative Analysis of the First Round of CMS Patient Listening Sessions for IRA’s Medicare DPNP
A new NPC publication in PharmacoEconomics – Open details learnings to help CMS improve the format and speaker representativeness of future patient-focused listening sessions.
Study Finds ICER’s Shared Saving Methods Reduce Incentives for Rare, Severe, and Pediatric Disease Treatment Innovation
New research published in Value in Health in collaboration with the National Pharmaceutical Council confirms the use of “shared saving” methods will diminish innovation incentives in areas of high…
The IRA May Have Unintended Consequences on Subsequent Indications of Oncology Drugs (New Research)
A new publication in Therapeutic Innovation & Regulatory Science examines drug-level trajectories toward subsequent indications in oncology and the way the IRA's Drug Price Negotiation…
Subsequent Indications in Oncology Drugs: Pathways, Timelines, and the Inflation Reduction Act
This study explores how drug-level post-approval development in cancer drugs may be impacted by changes to the incentives for drug development due to the Inflation Reduction Act’s (IRA) Medicare Drug…
The Inflation Reduction Act and Drug Development: Early Signals of Impact on Post-Approval Clinical Trials
At the inaugural Washington Health Economics Symposium (which took place in Washington, D.C. from October 7–8, 2024), NPC presented its latest research on the potential unintended consequences of the…
NPC Submits Comments Regarding the Medicare Hospital Outpatient Prospective Payment System
NPC submitted comments to CMS regarding the Medicare Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule for Calendar Year 2025.
NPC Submits Comments to CMS on Proposed Rule on CY 2025 Payment Policies and More
In response to CMS' request for comments, NPC shared its input on the proposed rule for payment policies under the Medicare Physician Fee Schedule for calendar year 2025.
NPC responds to CMS's Information Collection Request on the Negotiation Data Elements and Drug Price Negotiation Process for the Initial Price Applicability Year 2027
NPC offered the agency insights on the data collection requirements it has proposed to inform the second round of the the price-setting efforts in the Medicare Drug Price Negotiation Program.
The Accelerated Approval Program for Oncology Drugs: Celebrating More Than 250,000 Life-Years Gained and Counting
NPC’s commentary in AJMC examines evidence regarding the clinical benefit of the FDA’s Accelerated Approval Program and finds it is working for patients.
Analyzing Accelerated Approval for Oncology Drugs: NPC Commentary Evaluates Evidence on FDA Program Effectiveness, Concludes Benefits Outweigh Risks
A new publication in AJMC examines evidence regarding the clinical benefit of the FDA’s Accelerated Approval Program and finds it is working for patients